SandboxAQ Launches Virtual Screening Solution for GPCR Drug Discovery, Accelerated by NVIDIA BioNeMo - PR Newswire

SandboxAQ has launched a virtual screening solution for GPCR drug discovery, accelerated by NVIDIA's BioNeMo Agent Toolkit. GPCRs, which represent about one-third of all approved drugs, are notoriousl... Read original →

SandboxAQ’s GPCR virtual screening platform, powered by NVIDIA BioNeMo, marks a strategic pivot of large quantitative models from generic AI into structural pharmacology. This move forces a full-stack recalibration: upstream demand for 3nm/EUV-fabricated AI accelerators will surge, while downstream pharma must overhaul compute infrastructures to support LQMs and cuEquivariance-based workflows. Regulatory ambiguity around IP ownership of AI-generated molecular structures in the U.S. and EU may inflate legal overhead in early R&D. Competitors like Recursion or Insilico Medicine are likely to hedge against NVIDIA dependency by partnering with AMD or developing in-house accelerators. Within 18 months, 'AI-validated lead compounds' will become a critical fundraising benchmark, compelling biotechs to disclose computational validation data earlier—redefining VC valuation models where GPU clusters transition from cost centers to core R&D assets.